Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Tyra Biosciences, Inc. TYRA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
53/100
3/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$49.80
+41.2%

Tyra Biosciences, Inc. (TYRA) is a Biotechnology company in the Healthcare sector, currently trading at $35.27. It has a SharesGrow Score of 51/100, indicating a mixed investment profile with 3 out of 7 criteria passed.

Analyst consensus target is TYRA = $50 (+41.2% upside).

Valuation: TYRA trades at a trailing Price-to-Earnings (P/E) of -18.3 (S&P 500 average ~25).

Net income is $120M (loss), growing at -32.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $6M against $259M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 14.67 (strong liquidity). Debt-to-assets is 2.1%. Total assets: $283M.

Analyst outlook: 7 / 7 analysts rate TYRA as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 63/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

$49.80
▲ 41.2% Upside
Average Price Target
Based on 7 Wall Street analysts offering 12-month price targets for Tyra Biosciences, Inc., the average price target is $49.80, with a high forecast of $59.00, and a low forecast of $42.00.
Highest Price Target
$59.00
Average Price Target
$49.80
Lowest Price Target
$42.00

TYRA SharesGrow Score Overview

64/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 63/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TYRA

✓
VALUE Pass
63/100
TYRA trades at a trailing Price-to-Earnings (P/E) of -18.3 (S&P 500 average ~25). Forward PEG -1.62 — Peter Lynch undervalued (≤1.0). Trailing PEG 2.44. Analyst consensus target is $50, implying +41.8% from the current price $35. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
TYRA: +0%/yr revenue is, -32.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet TYRA: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 14.67 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
TYRA: Gross margin is 0% (+0 pp trend), $2B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 7 / 7 analysts rate TYRA as buy (100%). Analyst consensus target is $50 (+41.8% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range6.42-40.65
Volume1.39M
Avg Volume (30D)1.01M
Market Cap$1.89B
Beta (1Y)0.96
Share Statistics
EPS (TTM)-2.01
Shares Outstanding$59.6M
IPO Date2021-09-15
Employees60
CEOTodd Harris
Financial Highlights & Ratios
Gross Profit$-546K
EBITDA$-119.4M
Net Income$-119.95M
Operating Income$-132.76M
Total Cash$256M
Total Debt$5.81M
Net Debt$-71.58M
Total Assets$282.61M
Price / Earnings (P/E)-17.5
Analyst Forecast
1Y Price Target$50.00
Target High$59.00
Target Low$42.00
Upside+41.8%
Rating ConsensusBuy
Analysts Covering7
Buy 100% Hold 0% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS90240B1061

Price Chart

Track all markets on TradingView
TYRA
Tyra Biosciences, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
6.42 52WK RANGE 40.65

People Also View

ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 STOK
STOK
Stoke Therapeutics, Inc.
$35.86
+2.31%
 PHVS
PHVS
Pharvaris N.V.
$28.68
+2.87%
 MLYS
MLYS
Mineralys Therapeutics, Inc.
$27.32
+0.59%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 RAPT
RAPT
RAPT Therapeutics, Inc.
$58.01
+0.00%
 CGEM
CGEM
Cullinan Oncology, Inc.
$14.35
+0.70%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message